Fosamprenavir Calcium
FDA-approved product (tablet, oral), marketed as Fosamprenavir Calcium, Lexiva.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- HIV infection
- Immunodeficiency disease
- Viral disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Protease inhibitors
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE05; WHO ATC J05AE07
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA43.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli39.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae22.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis62.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Fosamprenavir Calcium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DichlorphenamideExisting use: Glaucoma73.9% AI-predicted activityagainst M. tuberculosisLab records exist2 registered studies
- Tamsulosin HydrochlorideExisting use: Benign prostatic hyperplasia, Prostate carcinoma73.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Thiethylperazine MalateExisting use: Allergic disease71.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease71.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more71.3% AI-predicted activityagainst M. tuberculosis26 registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder71.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma71.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more70.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydrochlorothiazideExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 9 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TolvaptanExisting use: Autosomal dominant polycystic kidney disease, Cardiovascular disease, Congestive heart failure and 4 more70.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more69.2% AI-predicted activityagainst M. tuberculosis5 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications
NCT00877591 · start 2008-04
Registered record
- Registry ID
- NCT00877591
- Conditions
- Opioid Dependency; HIV Infections
- Interventions
- Fosamprenavir/Ritonavir; Darunavir/Ritonavir; Rifampin; Rifabutin; Buprenorphine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-04
- Completion
- 2013-04
- Enrolment
- 63
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpioid Dependency; HIV InfectionsInterventionFosamprenavir/Ritonavir; Darunavir/Ritonavir; Rifampin; Rifabutin +1 morePhasePhase 1Registry statusCompletedAn Interaction Study to Assess Drug Levels in Healthy Adult Subjects
NCT00614991 · start 2008-01
Registered record
- Registry ID
- NCT00614991
- Conditions
- Healthy
- Interventions
- Raltegravir; Fosamprenavir; Ritonavir
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2008-01
- Completion
- 2008-03
- Enrolment
- 44
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionRaltegravir; Fosamprenavir; RitonavirPhaseNot applicableRegistry statusCompletedHIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults
NCT00450580 · start 2007-03
Registered record
- Registry ID
- NCT00450580
- Conditions
- Infection, Human Immunodeficiency Virus I; HIV-1 Infection
- Interventions
- fosamprenavir/ritonavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-03
- Completion
- 2008-08
- Enrolment
- 212
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfection, Human Immunodeficiency Virus I; HIV-1 InfectionInterventionfosamprenavir/ritonavirPhasePhase 3Registry statusCompletedClinical Trial of CNS-targeted HAART (CIT2)
NCT00624195 · start 2007-03
Registered record
- Registry ID
- NCT00624195
- Conditions
- HIV Infections
- Interventions
- FDA Approved Antiretroviral Therapy (see list below)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2007-03
- Completion
- 2012-06
- Enrolment
- 59
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionFDA Approved Antiretroviral Therapy (see list below)PhasePhase 2 / Phase 3Registry statusCompletedHepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions
NCT01908660 · start 2007-01
Registered record
- Registry ID
- NCT01908660
- Conditions
- Human Immunodeficiency Virus; Hepatitis B, Chronic; Hepatitis C, Chronic
- Interventions
- antiretroviral drugs
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2007-01
- Completion
- 2015-10
- Enrolment
- 192
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHuman Immunodeficiency Virus; Hepatitis B, Chronic; Hepatitis C, ChronicInterventionantiretroviral drugsPhaseNot recordedRegistry statusCompletedFractures Stratified by HIV and Antiretroviral Therapy (ART) Status
NCT01077557 · start 2006-11
Registered record
- Registry ID
- NCT01077557
- Conditions
- Fracture; Infection, Human Immunodeficiency Virus
- Interventions
- No Antiretroviral (ARV) Drug Exposure; Any Antiretroviral (ARV) Drug Exposure
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2006-11
- Completion
- 2011-11
- Enrolment
- 1
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFracture; Infection, Human Immunodeficiency VirusInterventionNo Antiretroviral (ARV) Drug Exposure; Any Antiretroviral (ARV) Drug ExposurePhaseNot recordedRegistry statusCompletedA Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects
NCT00363142 · start 2006-05
Registered record
- Registry ID
- NCT00363142
- Conditions
- HIV Infection; Infection, Human Immunodeficiency Virus
- Interventions
- Half-boosted Fosamprenavir; Full Boosted Fosamprenavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-05
- Completion
- 2008-06
- Enrolment
- 211
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infection; Infection, Human Immunodeficiency VirusInterventionHalf-boosted Fosamprenavir; Full Boosted FosamprenavirPhasePhase 3Registry statusCompletedA Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination
NCT00335270 · start 2006-03
Registered record
- Registry ID
- NCT00335270
- Conditions
- HIV
- Interventions
- fos-amprenavir calcium, ritonavir; abacavir/lamivudine as Epzicom
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-03
- Completion
- 2007-12
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIVInterventionfos-amprenavir calcium, ritonavir; abacavir/lamivudine as EpzicomPhasePhase 4Registry statusCompletedDual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)
NCT00122603 · start 2005-12
Registered record
- Registry ID
- NCT00122603
- Conditions
- HIV Infections
- Interventions
- Fosamprenavir; Saquinavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-12
- Completion
- 2007-08
- Enrolment
- 61
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionFosamprenavir; SaquinavirPhasePhase 2Registry statusCompletedA Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir
NCT00148785 · start 2005-07
Registered record
- Registry ID
- NCT00148785
- Conditions
- HIV Infections
- Interventions
- Indinavir/Ritonavir/Fosamprenavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2005-07
- Completion
- 2007-01
- Enrolment
- 15
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionIndinavir/Ritonavir/FosamprenavirPhasePhase 4Registry statusCompletedOpen Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects
NCT00144833 · start 2005-03
Registered record
- Registry ID
- NCT00144833
- Conditions
- HIV-1
- Interventions
- fosamprenavir/ritonavir (700mg/100mg BID); fosamprenavir/ritonavir (1400mg/100mg BID); fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2005-03
- Completion
- Not recorded
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV-1Interventionfosamprenavir/ritonavir (700mg/100mg BID); fosamprenavir/ritonavir (1400mg/100mg BID); fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID)PhasePhase 3Registry statusTerminated"The Once A Day Protease Inhibitor Regimens"
NCT00242216 · start 2004-05
Registered record
- Registry ID
- NCT00242216
- Conditions
- HIV Infections
- Interventions
- ritonavir-boosted atazanavir; ritonavir-boosted fosamprenavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2004-05
- Completion
- 2010-03
- Enrolment
- 76
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionritonavir-boosted atazanavir; ritonavir-boosted fosamprenavirPhasePhase 4Registry statusCompletedStudy Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
NCT00071760 · start 2003-10-23
Registered record
- Registry ID
- NCT00071760
- Conditions
- Infection, Human Immunodeficiency Virus; HIV Infections
- Interventions
- GW433908; ritonavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-10-23
- Completion
- 2022-03-29
- Enrolment
- 59
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfection, Human Immunodeficiency Virus; HIV InfectionsInterventionGW433908; ritonavirPhasePhase 2Registry statusCompletedFosamprenavir Expanded Access
NCT00240552 · start 2003-07
Registered record
- Registry ID
- NCT00240552
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- fosamprenavir; Telzir®
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2003-07
- Completion
- 2005-08
- Enrolment
- 85
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfection, Human Immunodeficiency VirusInterventionfosamprenavir; Telzir®PhasePhase 4Registry statusCompletedPharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
NCT00042289 · start 2003-06-09
Registered record
- Registry ID
- NCT00042289
- Conditions
- HIV Infections
- Interventions
- atazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3; elvitegravir/cobicistat; dolutegravir; tenofovir alafenamide fumarate (TAF); TAF w/cobicistat; TAF w/cobicistat or ritonavir; efavirenz; darunavir/cobicistat; lopinavir/ritonavir dosage #1; atazanavir/ritonavir/tenofovir dosage #1; rifampicin; ethambutol; isoniazid; pyrazinamide; kanamycin; amikacin; capreomycin; moxifloxacin; levoflaxacin; ofloxacin; ethionamide/prothionamide; terizidone/cycloserine; para-aminosalicylic acid (PAS); high dose INH; bedaquiline; clofazamine; delamanid; linezolid; pretomanid; ethinyl estradiol; etonogestrel implant; nevirapine; amprenavir; abacavir; lopinavir/ritonavir dosage #2; indinavir/ritonavir dosage #1; fosamprenavir/ritonavir; lopinavir/ritonavir dosage #3; atazanavir/ritonavir dosage #1; didanosine delayed release (Videx® EC); emtricitabine; tenofovir; nelfinavir dosage #1; tipranavir/ritonavir; lopinavir/ritonavir dosage #4; ralteg
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2003-06-09
- Completion
- 2020-09-30
- Enrolment
- 1,578
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionatazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3 +45 morePhaseNot recordedRegistry statusCompleted